Drug Trial Radar · NCT02140255
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,120
Planned (sponsor's estimate)
Start
Jan 23, 2015
Primary completion
Jan 31, 2028
Study completion Dec 31, 2031
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
- First posted
- May 16, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 48 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.
Conditions
- HIV Infection
Interventions
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Drug
Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
Nevirapine (NVP)Drug
Administered orally. Dosed according to study step/participant's age/participant's weight.
Lopinavir/Ritonavir (LPV/r)Drug
Administered orally. Dosed according to study step and participant's age.
Raltegravir (RAL)Drug
Administered orally. Dosed according to study step and participant's age.
VRC01Drug
40 mg/kg administered subcutaneously.
Dolutegravir (DTG)Drug
Dosed according to study step/participant's age/participant's weight
VRC07-523LSDrug
40 mg/kg administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who achieve HIV remissionTime frame: Measured through Week 48
Locations
47 sites in 13 countries. Site status is shown where the registry gives one.
4601, University of California, San Diego Clinical Research Site
La Jolla, California · Completed
5048, University of Southern California Clinical Research Site
Los Angeles, California · Recruiting
5112, David Geffen School of Medicine at UCLA Clinical Research Site
Los Angeles, California · Recruiting
5052, University of Colorado, Denver Clinical Research Site
Aurora, Colorado · Recruiting
5055, South Florida CDTC Fort Lauderdale Clinical Research Site
Fort Lauderdale, Florida · Completed
5051, University of Florida Center for HIV/AIDS Research, Education and Service (UF CARES) Clinical Research Site
Jacksonville, Florida · Recruiting
5127, Pediatric Perinatal HIV Clinical Research Site
Miami, Florida · Withdrawn
Emory University School of Medicine NICHD CRS
Atlanta, Georgia · Withdrawn
32515, Rush Univ./Cook County Hosp. Chicago CRS
Chicago, Illinois · Recruiting
5083, Rush University Cook County Hospital Clinical Research Site
Chicago, Illinois · Withdrawn
4001, Lurie Children's Hospital of Chicago Clinical Research Site
Chicago, Illinois · Recruiting
5092, Johns Hopkins Clinical Research Site
Baltimore, Maryland · Recruiting
Boston Medical Center Ped. HIV Program NICHD CRS
Boston, Massachusetts · Withdrawn
5040, SUNY Stony Brook Clinical Research Site
Stony Brook, New York · Withdrawn
5114, Bronx Lebanon Hospital Center Clinical Research Site
The Bronx, New York · Recruiting
5013, Jacobi Medical Center Clinical Research Site
The Bronx, New York · Recruiting
Philadelphia IMPAACT Unit CRS
Philadelphia, Pennsylvania · Withdrawn
6501, St Jude Children's Research Hospital Clinical Research Site
Memphis, Tennessee · Recruiting
5128, Baylor College of Medicine/Texas Children's Hospital Clinical Research Site
Houston, Texas · Recruiting
Seattle Children's Research Institute CRS
Seattle, Washington · Withdrawn
Univ. of Washington NICHD CRS
Seattle, Washington · Withdrawn
Hosp. General de Agudos Buenos Aires Argentina NICHD CRS
Buenos Aires, Argentina · Withdrawn
5073, School of Medicine Federal University Minas Gerais Clinical Research Site
Minas Gerais, Brazil · Recruiting
5072, Hospital Federal dos Servidores do Estado Clinical Research Site
Rio de Janeiro, Brazil · Completed
5071, Instituto de Puericultura e Pediatria Martagao Gesteira Clinical Research Site
Rio de Janeiro, Brazil · Recruiting
5097, Hospital Geral de Nova Igaucu Clinical Research Site
Rio de Janeiro, Brazil · Completed
5074, University of Sao Paulo Clinical Research Site
São Paulo, Brazil · Completed
Hospital Nossa Senhora da Conceicao NICHD CRS
Porto Alegre, Rio Greande Do Sul, Brazil · Completed
30022, Les Centres GHESKIO Clinical Research Site
Port-au-Prince, Haiti · Recruiting
5121, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center Kericho Clinical Research Site
Kericho, Kenya · Recruiting
30301, Blantyre Clinical Research Site
Blantyre, Malawi · Recruiting
12001, Malawi Clinical Research Site
Lilongwe, Central Region, Malawi · Recruiting
32513, IMPAACT/ Gamma Project/ UPR Pediatric HIV/AIDS Research Network CRS
San Juan, PR, Puerto Rico · Withdrawn
San Juan City Hosp. PR NICHD CRS
San Juan, Puerto Rico, Puerto Rico · Withdrawn
Soweto IMPAACT CRS
Johannesburg, Gauteng, South Africa · Completed
Wits RHI Shandukani Research Centre CRS
Johannesburg, Gauteng, South Africa · Completed
30300, Umlazi Clinical Research Site
Durban, KwaZulu-Natal, South Africa · Recruiting
8950, FAMCRU Clinical Research Site
Tygerberg, Western Cape, South Africa · Completed
5118, Kilimanjaro Christian Medical Centre Clinical Research Site
Moshi, Tanzania · Recruiting
5116, Chiangrai Prachanukroh Hospital Clinical Research Site
Chiang Mai, Thailand · Recruiting
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.